Senores Pharmaceuticals (NSE:SENORES) Retained Earnings: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
18 GF Score
Price ₹1,492.40
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals Retained Earnings?

Senores Pharmaceuticals NSE:SENORES +1.13% 18 Retained Earnings is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 18/100. The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Senores Pharmaceuticals's retained earnings for the quarter that ended in Jun. 2026 was ₹0 Mil.

Senores Pharmaceuticals's annual retained earnings increased from Mar. 2024 (₹416 Mil) to Mar. 2025 (₹899 Mil) but then declined from Mar. 2025 (₹899 Mil) to Mar. 2026 (₹0 Mil).


Senores Pharmaceuticals  (NSE:SENORES) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Senores Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals Retained Earnings Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
16.80 101.13 415.80 899.10 0.00

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SENORES
18GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹0 Mil mean?
Senores Pharmaceuticals (NSE:SENORES) has a Retained Earnings of ₹0 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' Retained Earnings too high?
Senores Pharmaceuticals' current Retained Earnings is ₹0 Mil. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' Retained Earnings compare to LLY and JNJ?
Senores Pharmaceuticals' Retained Earnings of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current Retained Earnings is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current Retained Earnings of ₹0 Mil. The current Retained Earnings is ₹0 Mil. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current Retained Earnings is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score

Get the complete analysis for NSE:SENORES

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,492.40
Price